Transaction DateRecipientSharesTypePriceValue
20th October 2020Joana Goncalves2,000Open or private sale$15.00$30,000.00
3rd September 2020Derek T Chalmers3,201Open or private sale$16.00$51,216.00
3rd August 2020Derek T Chalmers5,000Open or private sale$16.42$82,100.00
1st July 2020Derek T Chalmers5,000Open or private sale$17.11$85,550.00
12th June 2020Joana Goncalves10,627Open or private sale$15.20$161,530.40
10th June 2020Joana Goncalves30,000Grant/award etc.$0.00
4th June 2020Harrison M Jr Bains7,200Grant/award etc.$0.00
4th June 2020Jeffrey L. Ives7,200Grant/award etc.$0.00
4th June 2020Christopher Posner7,200Grant/award etc.$0.00
4th June 2020Martin Vogelbaum14,400Grant/award etc.$0.00
Cara Therapeutics
Cara Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frédérique Menzaghi on July 2, 2004.


Ticker: CARA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1346830
Employees: 67
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $57 M (0%)
Assets, Current: $142 M (-14%)
Property, Plant and Equipment, Net: $604 Th (-13%)
Assets: $169 M (-27%)
Accounts Payable, Current: $5 M (-46%)
Liabilities, Current: $25 M (-42%)
Common Stock, Value, Issued: $47 Th (0%)
Common Stock, Shares, Issued: $47 M (0%)
Additional Paid in Capital, Common Stock: $595 M (1%)
Retained Earnings (Accumulated Deficit): $455 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $635 Th (273%)
Stockholders' Equity (Parent): $141 M (0%)
Liabilities and Equity: $169 M (-27%)
Revenue: $6 M (-58%)
Research and Development: $26 M (-56%)
General and Administrative Expenses: $5 M (-45%)
Operating Income/Loss: $26 M (-53%)
Provision for income taxes: $182 Th (0%)